Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

Fiorella Di Pastena,Gregory Pond,Evangelia E. Tsakiridis,Andre Gouveia,Elham Ahmadi,Olga-Demetra Biziotis,Amr Ali,Anand Swaminath,Gordon Okawara,Peter M. Ellis,Bassam Abdulkarim,Naseer Ahmed,Andrew Robinson,Wilson Roa,Mario Valdes,Peter Kavsak,Marcin Wierzbicki,James Wright,Gregory Steinberg,Theodoros Tsakiridis
DOI: https://doi.org/10.1186/s13014-024-02546-y
IF: 4.309
2024-11-09
Radiation Oncology
Abstract:Growth differentiation factor 15 (GDF15) is a cytokine of the TGFβ family. Here, we analyzed GDF15 levels in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who participated in OCOG-ALMERA (NCT02115464), a phase II randomized clinical trial, that investigated metformin in combination with standard of care concurrent chemoradiotherapy (cCRT). OCOG-ALMERA was not able to demonstrate benefit in the metformin arm. Therefore, biomarker studies are needed to better define stratification parameters for future trials.
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?